Harmony Biosciences Receives U.S. FDA Approval for WAKIX (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
“We are excited to achieve this important milestone for pediatric narcolepsy patients who experience cataplexy,” said Kumar Budur, M.D., M.S., Chief Medical and Scientific Officer of Harmony Biosciences. “With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy.”Go to Article
Get ready for the evolution in sleep medicine with Sleep Medicine Trends! Discover vital insights on the latest innovations and strategies to thrive in the field. This event is your gateway to understanding the latest trends, care delivery methods, strategic approaches, and sustainable practices that will empower you as a sleep professional. This year, we’re excited to introduce the Business of Sleep Medicine Add-On Course, offering practical strategies for today’s healthcare landscape. Elevate your practice and become a leader in the field of sleep medicine. Register today!
.png?upscale=true&width=200&upscale=true&name=psc%20logo_transparent%20(2).png)
%20(1).png?upscale=true&width=1200&upscale=true&name=KPAP%20Town%20Hall%20(600%20x%20200%20px)%20(1).png)